Sprint Bioscience Q1 2023: VADA deal needed
Research Update
2023-05-11
06:45
Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near future to strengthen its financial position.
CB
EL
Christian Binder
Ethel Luvall
Disclosures and disclaimers